Despite oil prices retreating due to data showing slowing Chinese manufacturing and easing Ukraine tensions, Dan Dicker still sees opportunity in U.S. oil companies.
TheStreet's Jim Cramer says he is completely neutral on Mannkind and sometimes it's better to admit you don't know where something is going.
Jim Cramer says the latest ADP jobs number shows a 'mixed picture' in the U.S. labor market and that even though autos have been strong, which is a big driver, mortgages are down and housing may not be a big number.
TheStreet's Jim Cramer says one of the themes investors should pay close attention to is oil and the opportunities for investment it presents.
TheStreet's Jim Cramer says investors need to see money come back to high-growth names, which have seen a shrinking price-to-earnings multiple.
Jim Cramer says markets appear to be brushing-off weak PMI data from China because expectations were already low, and while industrials may be slowing down, consumption names are gaining speed.
Johnson & Johnson is selling its Ortho-Clinical Diagnostics business to The Carlyle Group for $4 billion.
Jim Cramer answers viewer questions on Dish Networks, solar investing and Starbucks.
TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.
Jim Cramer discusses the mixed signals in the market regarding what sort of nonfarm payrolls report we will receive this week.